Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Shockwave Medical $750 million convertible senior notes offering
The 1% convertible notes are due 2028
Cano Health amendment and covenant waiver for side-car credit facility
We advised Rubicon Founders in connection with the transaction
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition
Gracell Biotechnologies PIPE of ordinary shares and warrants
The company’s ADSs are listed on Nasdaq
Recursion Pharmaceuticals $300 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
NGM Biopharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Allurion Technologies merger with Compute Health Acquisition
We advised the capital markets adviser on the de-SPAC transaction
Immedica Pharma acquisition of pegzilarginase assets from Aeglea
We advised Immedica on the transaction
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics